三款自动免疫组织化学染色仪在乳腺癌病理诊断中的应用比较

doi:10.16150/j.1671-2870.2017.06.016

摘要/Abstract

摘要： 目的: 比较三款常用的全自动免疫组织化学染色仪处理乳腺浸润性导管癌标本在病理诊断中的应用价值。方法: 选取30例患者的乳腺浸润性导管癌组织各1块,切取层厚3 μm的石蜡切片12张,分别使用三款常用的全自动免疫组织化学染色仪进行雌激素受体（estrogen receptor,ER）、孕激素受体（progesterone receptor,PR）、人表皮生长因子受体2（human epidermal growth factor receptor 2,HER-2）及和Ki-67染色,分析、比较采用3种仪器处理标本后,标本的4个免疫组织化学指标的阳性率。结果: 染色仪A处理的标本,ER阳性18例（10%~99%,+~+++）,PR阳性14例（1%~99%,+~+++）,HER-2阳性29例（+~+++）,Ki-67阳性30例（5%~90%,+）;染色仪B处理的标本,ER阳性18例（10%~99%,+~+++）,PR阳性12例（1%~99%,+~+++）,HER-2阳性28例（+~+++）,Ki-67阳性30例（5%~90%,+）;染色仪C处理的标本,ER阳性18例（10%~99%,+~+++）、PR阳性12例（5%~90%,+~+++）,HER-2阳性28例（+~+++）、Ki-67阳性30例（5%~90%,+）。经卡方检验结果显示,三款免疫组织化学染色仪处理标本后,各指标间具有一致性（P>0.05）。结论: 三款常用的全自动免疫组织化学染色仪处理组织切片后, ER、PR、HER-2、Ki-67的病理诊断结果间差异无统计学意义,提示这3种仪器处理病理标本的结果具有一致性。

关键词: 全自动免疫组织化学染色仪, 乳腺癌, 免疫组织化学, 病理诊断

Abstract: Objective: To investigate the performance of 3 types of automatic immunohistochemical stainer(Leica Bond-Max, Dako Omnis and BenchMark Ultra automatic immunohistochemical stainer) in pathological diagnosis of invasive ductal carcinoma of breast. Methods: Paraffin-embedded tissue blocks from 30 patients with infiltrating ductal carcinoma were collected,and 12 sections with a thickness of 3 μm were excised from each paraffin-embedded tissue block. After being stained with these three types of automatic immunohistochemical stainer, the specimens were examined to determine the expressions of estrogen receptor(ER）, progesterone receptor (PR）, human epidermal growth factor receptor 2（HER-2） and Ki67. Positive rates of above mentioned parameters between specimens prepared with these three different stainers were compared. Results: For Leica Bond-Max, the cases with positive ER(10%-99%, +~+++）, PR(1%-99%, +~+++）, HER-2（+~+++） and Ki-67（5%-90%, +）were 18, 14, 29 and 30 cases, respectively, by Dako Omnis were 18, 12, 28 and 30 cases, respectively, and by BenchMark Ultra were 18, 12, 28 and, 30 cases, respectively. There were no significant differences in positive expressions of these parameters in specimens prepared with these 3 types of automatic immunohistochemical stainer(P>0.05). Conclusions: Pathologic results of ER, PR, HER-2 and Ki-67 expression in breast carcinoma tissue were similar when specimens were prepared with these three types of automatic immunohistochemical stainer, indicating that specimens could be prepared with any type of above mentioned automatic immunohistochemical stainer.

Key words: Automatic immunohistochemical stainer, Breast cancer, Pathological diagnosis

中图分类号:

R541.7

许海敏, 张培培. 三款自动免疫组织化学染色仪在乳腺癌病理诊断中的应用比较[J]. 诊断学理论与实践, 2017, 16(06): 645-649.

XU Haimin, ZHANG Peipei. Comparison of performance between three types of automatic immunohistochemical stainer in pathological diagnosis of breast cancer[J]. Journal of Diagnostics Concepts & Practice, 2017, 16(06): 645-649.

参考文献

[1] Siegel R, Naishadham D, Jemal A.Cancer statistics, 2013[J]. CA Cancer J Clin,2013,63(1):11-30.
[2] IARC, world cancer report 2014[R]. report 2014[R]. Lyon: IARC,2014:509.
[3] Song F, He M, Li H, et al.A cancer incidence survey in Tianjin: the third largest city in China-between 1981 and 2000[J]. Cancer Causes Control,2008,19(5):443-450.
[4] 顾林, 王平. 乳腺癌[M]. 北京: 科学技术文献出版社,2010:174-175.
[5] 李世超, 剂晓伟, 范林军. 美国临床肿瘤学会和美国病理学家学会乳腺癌雌/孕激素受体免疫组化检测指南[J]. 中华乳腺病杂志,2011,5(3):385-386.
[6] 程元甲, 叶京明, 徐玲, 等. 乳腺癌新辅助治疗病理完全缓解预测因素分析[J]. 中华外科杂志,2013,51(4):339-340.
[7] 沈镇宙, 邵志敏. 乳腺肿瘤学[M]. 上海: 上海科学技术出版社,2005:14.
[8] 《乳腺癌HER2检测指南(2014版)》编写组. 乳腺癌HER2检测指南(2014版)[J]. 中华病理学杂志,2014,43(4):262-267.
[9] 《乳腺癌雌、孕激素受体免疫组织化学检测指南》编写组. 乳腺癌雌、孕激素受体免疫组织化学检测指南[J]. 中华病理学杂志,2015,44(4):237-239.
[10] Dowsett M, Houghton J, Iden C, et al.Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status[J]. Ann Oncol,2006,17(5):818-826.
[11] van de Vijver MJ. Assessment of the need and appro-priate method for testing for the human epidermal growth factor receptor-2 (HER2)[J]. Eur J Cancer,2001,37(Suppl 1):11-17.
[12] Disis ML, Schiffman K.Cancer vaccines targeting the HER2/neu oncogenic protein[J]. Semin Oncol,2001,28(6 Suppl 18):12-20.
[13] Hayes DF, Yamauchi H, Broadwater G, et al.Circulating HER-2/erbB-2/c-neu(HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662[J]. Clin Cancer Res,2001,7(9):2703-2711.
[14] Morales L, Reigosa A, Caleiras E, et al.HER2/neu expression in Venezuelan patients with locally advanced breast cancer[J]. Invest Clin,2008,49(1):69-78.
[15] Ma WW, Adjei AA.Novel agents on the horizon for cancer therapy[J]. CA Cancer J Clin,2009,59(2):111-137.
[16] Coates PJ, Hobbs RC, Crocker J, et al.Identification of the antigen recognized by the monoclonal antibody BU31 as lamins A and C[J]. J Pathol,1996,178(1):21-29.
[17] Liu M, Lawson G, Delos M, et al. Predictive value of the fraction of cancer cells immunolabeled for proliferating cell nuclear antigen or Ki67 in biopsies of head and neck carcinomas to identify lymph node metastasis: comparison with clinical and radiologic examinations[J]. Head Neck, 2003 Apr,25(4):280-288.
[18] Dowsett M, Smith IE, Ebbs SR, et al.Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer[J]. J Natl Cancer Inst,2007,99(2):167-170.
[19] Stathopoulos GP, Malamos NA, Markopoulos C, et al.The role of Ki-67 in the proliferation and prognosis of breast cancer molecular classification subtypes[J]. Anticancer Drugs,2014,25(8):950-957.
[20] Polley MY, Leung SC, McShane LM, et al. An international Ki67 reproducibility study[J]. J Natl Cancer Inst,2013,105(24):1897-1906.
[21] 胡传朋, 刘勇, 程宝智, 等. HER-2和Ki67在激素依赖性乳腺癌中的表达及其临床意义[J]. 安徽医学,2017, 38(4):450-452,453.
[22] 高名士, 张佳诚, 汪寅. Leica BOND-MAXTM全自动免疫组织化学染色机Covertile清洁方法探讨[J]. 中华病理学杂志,2013,42(3):199-200.
[23] 刘玉山, 周建云, 赵斌. 全自动免疫组织化学染色系统的使用对比分析[J]. 实用医技杂志,2016,23(7):760-761.